Shandong Xinhua Pharmaceutical Company Limited

SZSC:719 Stock Report

Market Cap: HK$9.3b

Shandong Xinhua Pharmaceutical Past Earnings Performance

Past criteria checks 2/6

Shandong Xinhua Pharmaceutical has been growing earnings at an average annual rate of 11.4%, while the Pharmaceuticals industry saw earnings growing at 4.3% annually. Revenues have been growing at an average rate of 9.5% per year. Shandong Xinhua Pharmaceutical's return on equity is 9.1%, and it has net margins of 5.4%.

Key information

11.4%

Earnings growth rate

9.0%

EPS growth rate

Pharmaceuticals Industry Growth5.6%
Revenue growth rate9.5%
Return on equity9.1%
Net Margin5.4%
Next Earnings Update31 Mar 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Shandong Xinhua Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SZSC:719 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 248,3374491,097405
30 Jun 248,1614921,155427
31 Mar 247,9364871,189449
31 Dec 238,1014971,298419
30 Sep 238,5475101,354428
30 Jun 238,5114861,347413
31 Mar 238,3114541,325379
01 Jan 237,5034111,111346
30 Sep 227,073357980352
30 Jun 226,673343900340
31 Mar 226,623357908343
31 Dec 216,560349931341
30 Sep 216,307364935338
30 Jun 216,271353992311
31 Mar 216,068339957301
31 Dec 206,006325944298
30 Sep 205,814305982261
30 Jun 205,769323990260
31 Mar 205,6823101,049253
31 Dec 195,6063001,105235
30 Sep 195,7163031,107229
30 Jun 195,6802811,072233
31 Mar 195,4572641,012201
31 Dec 185,245255924187
30 Sep 185,023229859172
30 Jun 184,800226809151
31 Mar 184,638226710204
31 Dec 174,516210725161
30 Sep 174,491207718130
30 Jun 174,42018376297
31 Mar 174,3061547990
31 Dec 164,0151227240
30 Sep 163,8001106670
30 Jun 163,6471036240
31 Mar 163,602896110
31 Dec 153,597836110
30 Sep 153,604646130
30 Jun 153,678365930
31 Mar 153,653626040
31 Dec 143,590515650
30 Sep 143,769526140
30 Jun 143,635745890
31 Mar 143,588505440

Quality Earnings: 719 has high quality earnings.

Growing Profit Margin: 719's current net profit margins (5.4%) are lower than last year (6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 719's earnings have grown by 11.4% per year over the past 5 years.

Accelerating Growth: 719's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 719 had negative earnings growth (-12%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (9.4%).

Return on Equity

High ROE: 719's Return on Equity (9.1%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/01 16:47
End of Day Share Price 2024/12/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shandong Xinhua Pharmaceutical Company Limited is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alex FanGF Securities (Hong Kong) Brokerage Limited
Ming LiIndustrial Securities Co. Ltd.
Guohe FanPhillip Securities (HK)